search
Back to results

Quantification of the Airflow Into Sinuses Before and After ArchSinus Implantation

Primary Purpose

Chronic Sinusitis, Ethmoidal

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
ArchSinus implantation
Sponsored by
STS Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Sinusitis, Ethmoidal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male/female, 18 year or older Diagnosis of chronic rhinosinusitis defined as symptomatic inflammation of the sinuses of at least 12 consecutive weeks duration despite medical management ≥ 3 months post primary FESS Symptoms of chronic rhinosinusitis defined as ≥ 10 score on SNOT-22 Middle turbinate lateralization defined as ˃ 2 score on MT lateralization scale Exclusion Criteria: Polyp grade ˃ 4 bilaterally on Lildholdt's scale (1-3) Sinonasal tumors Known allergy to nickel Known polyurethane induced dermatitis History of immune deficiency Cystic fibrosis Pregnant or lactating female Acute sinus inflammation Coagulation disorders

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    ArchSinus implantation

    Arm Description

    Subjects will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation

    Outcomes

    Primary Outcome Measures

    Sinus airflow and particle deposition rate
    The primary objective of this study aims to compare the sinonasal airflow rate and particle deposition rate at Baseline and 12 weeks after the ArchSinus stent implantation, based on CFD analysis.

    Secondary Outcome Measures

    Symptomatic improvement
    The secondary objective of this study is to analyze correlation between an increased sinus airflow and symptomatic improvement, assessed using SNOT-22 and NOSE Questioners, at baseline and at 1, 6 and 12 weeks after the ArchSinus stent removal.

    Full Information

    First Posted
    January 29, 2023
    Last Updated
    May 15, 2023
    Sponsor
    STS Medical
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05863468
    Brief Title
    Quantification of the Airflow Into Sinuses Before and After ArchSinus Implantation
    Official Title
    Quantification of the Airflow Into Sinuses Before and After ArchSinus Implantation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 15, 2023 (Anticipated)
    Primary Completion Date
    November 21, 2023 (Anticipated)
    Study Completion Date
    December 21, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    STS Medical

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a single-center, single-arm, interventional case study designed to compare the sinonasal airflow and symptomatic status of four (4) chronic sinusitis patients, before and after the ArchSinus stent implantation.
    Detailed Description
    This is a single-center, single-arm, interventional case study. This case study is designed to compare the sinonasal airflow and symptomatic status of four (4) chronic sinusitis patients who after undergoing primary FESS were seen to have symptomatic lateralization of the middle turbinate and underwent medialization of the middle turbinate accompanied by ArchSinus stent implantation. Patient eligibility will be confirmed based on the endoscopic examination and SNOT-22 score. Patient history will be taken, specifically which if any nasal spacer was used after the primary FESS. 4 chronic sinusitis patients that suffer from middle turbinate lateralization and symptomatic deterioration, 3-6 months after primary FESS, that met the inclusion / exclusion criteria, will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation. The stents will be removed 2-3 weeks after procedure. CT scan will be performed at baseline and 12 weeks after the ArchSinus stent removal, and 3D sinonasal airways reconstruction of the maxillary, ethmoid, sphenoid & frontal sinuses will be performed. Subsequently, airflow and particle deposition will be simulated in each reconstruction, and airflow rate and particle deposition will be quantified for different sinuses. Symptomatic status will be analyzed at baseline and 1, 6 and 12 weeks after the ArchSinus stent removal using SNOT-22 and NOSE Questioners. Debridement is disallowed during the ArchSinus implantation time period. Nasal decongestions are disallowed prior to CT scan examination.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Sinusitis, Ethmoidal

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    4 chronic sinusitis patients will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation. Baseline and 12-week airflow rate and particle deposition will be analyzed with Computational Modeling Analysis. symptomatic improvement will be analyzed using SNOT-22 and NOSE questioners.
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    4 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    ArchSinus implantation
    Arm Type
    Experimental
    Arm Description
    Subjects will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
    Intervention Type
    Device
    Intervention Name(s)
    ArchSinus implantation
    Intervention Description
    Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
    Primary Outcome Measure Information:
    Title
    Sinus airflow and particle deposition rate
    Description
    The primary objective of this study aims to compare the sinonasal airflow rate and particle deposition rate at Baseline and 12 weeks after the ArchSinus stent implantation, based on CFD analysis.
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Symptomatic improvement
    Description
    The secondary objective of this study is to analyze correlation between an increased sinus airflow and symptomatic improvement, assessed using SNOT-22 and NOSE Questioners, at baseline and at 1, 6 and 12 weeks after the ArchSinus stent removal.
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male/female, 18 year or older Diagnosis of chronic rhinosinusitis defined as symptomatic inflammation of the sinuses of at least 12 consecutive weeks duration despite medical management ≥ 3 months post primary FESS Symptoms of chronic rhinosinusitis defined as ≥ 10 score on SNOT-22 Middle turbinate lateralization defined as ˃ 2 score on MT lateralization scale Exclusion Criteria: Polyp grade ˃ 4 bilaterally on Lildholdt's scale (1-3) Sinonasal tumors Known allergy to nickel Known polyurethane induced dermatitis History of immune deficiency Cystic fibrosis Pregnant or lactating female Acute sinus inflammation Coagulation disorders

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Quantification of the Airflow Into Sinuses Before and After ArchSinus Implantation

    We'll reach out to this number within 24 hrs